Beck-Sickinger AG - Search Results

1

Chemical and biological characterization of new Re(CO)3/[99mTc](CO)3 bombesin analogues.

García Garayoa E, Rüegg D, Bläuenstein P, Zwimpfer M, Khan IU, Maes V, Blanc A, Beck-Sickinger AG, Tourwé DA, Schubiger PA. García Garayoa E, et al. Nucl Med Biol. 2007 Jan;34(1):17-28. doi: 10.1016/j.nucmedbio.2006.10.004. Epub 2006 Nov 28. Nucl Med Biol. 2007. PMID: 17210458

2

Improving the tumor uptake of 99mTc-labeled neuropeptides using stabilized peptide analogues.

Bläuenstein P, Garayoa EG, Rüegg D, Blanc A, Tourwé D, Beck-Sickinger A, Schubiger PA. Bläuenstein P, et al. Cancer Biother Radiopharm. 2004 Apr;19(2):181-8. doi: 10.1089/108497804323071959. Cancer Biother Radiopharm. 2004. PMID: 15186598

3

In vitro and in vivo evaluation of a 99mTc(I)-labeled bombesin analogue for imaging of gastrin releasing peptide receptor-positive tumors.

La Bella R, Garcia-Garayoa E, Langer M, Bläuenstein P, Beck-Sickinger AG, Schubiger PA. La Bella R, et al. Nucl Med Biol. 2002 Jul;29(5):553-60. doi: 10.1016/s0969-8051(02)00314-1. Nucl Med Biol. 2002. PMID: 12088725

4

New [99mTc]bombesin analogues with improved biodistribution for targeting gastrin releasing-peptide receptor-positive tumors.

García Garayoa E, Schweinsberg C, Maes V, Rüegg D, Blanc A, Bläuenstein P, Tourwé DA, Beck-Sickinger AG, Schubiger PA. García Garayoa E, et al. Q J Nucl Med Mol Imaging. 2007 Mar;51(1):42-50. Q J Nucl Med Mol Imaging. 2007. PMID: 17372572 Free article.

5

99mTc-labeled neuropeptide Y analogues as potential tumor imaging agents.

Langer M, La Bella R, Garcia-Garayoa E, Beck-Sickinger AG. Langer M, et al. Bioconjug Chem. 2001 Nov-Dec;12(6):1028-34. doi: 10.1021/bc015514h. Bioconjug Chem. 2001. PMID: 11716696

6

Targeted tumor diagnosis and therapy with peptide hormones as radiopharmaceuticals.

Khan IU, Beck-Sickinger AG. Khan IU, et al. Anticancer Agents Med Chem. 2008 Feb;8(2):186-99. doi: 10.2174/187152008783497046. Anticancer Agents Med Chem. 2008. PMID: 18288921 Review.

7

Novel chemically modified analogues of neuropeptide Y for tumor targeting.

Zwanziger D, Khan IU, Neundorf I, Sieger S, Lehmann L, Friebe M, Dinkelborg L, Beck-Sickinger AG. Zwanziger D, et al. Bioconjug Chem. 2008 Jul;19(7):1430-8. doi: 10.1021/bc7004297. Epub 2008 Jun 24. Bioconjug Chem. 2008. PMID: 18572959

8

Identification of neuropeptide Y cleavage products in human blood to improve metabolic stability.

Khan IU, Reppich R, Beck-Sickinger AG. Khan IU, et al. Biopolymers. 2007;88(2):182-9. doi: 10.1002/bip.20666. Biopolymers. 2007. PMID: 17206650

9

Breast-cancer diagnosis by neuropeptide Y analogues: from synthesis to clinical application.

Khan IU, Zwanziger D, Böhme I, Javed M, Naseer H, Hyder SW, Beck-Sickinger AG. Khan IU, et al. Angew Chem Int Ed Engl. 2010 Feb 1;49(6):1155-8. doi: 10.1002/anie.200905008. Angew Chem Int Ed Engl. 2010. PMID: 20104470 No abstract available.

10

A rational approach for the development of reduced-size analogues of neuropeptide Y with high affinity to the Y1 receptor.

Rist B, Wieland HA, Willim KD, Beck-Sickinger AG. Rist B, et al. J Pept Sci. 1995 Sep-Oct;1(5):341-8. doi: 10.1002/psc.310010509. J Pept Sci. 1995. PMID: 9223013

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

411 results

Search Page

Filters